Selected results of proof-of-concept studies with m-det

M-DET-56 platform


Many projects have been done with out M-Det-56 proof-of-concept platform. Here we present some of these results to demonstrate the power of M-DET approach for differential diagnosis of breast and ovarian cancers.

Obviously, the more fragments we test to find those few that will be the best for a specific task, the better will be the results. Here we show (image in the next section) the difference between Proof-of-Concept M-Det-56 and M-Det-244k platforms. 

Imagine how much better will be the results for your project! 

Sensitivity and Specificity


An example of Proof-of-Concept results for differential diagnosis of breast and ovarian cancers (here the Proof-of Concept M-DET-56 was used to select informative fragments):

Breast cancer   

                                               Sensitivity  Specificity

Healthy vs. DCIS               80%               88%                 

Healthy vs. IDC                   87%               85%                 

IDC vs. DCIS                        87%               76%                 

Ovarian cancer            

                                               Sensitivity  Specificity           

Healthy vs. OvCa              89%               79%                 

Healthy vs. Benign          74%               78%                 

Benign vs. OvCa              82%               71%                 

From Proof-of-Concept to Discovery


Increasing the number of tested sites from 56 to 244,000 allows us to:

  • Select better components for the composite biomarker;
  • Increase the sensitivity  and the specificity of the biomarker
  • Improve accuracy and reduce errors
  • Reduce false-positives and false negatives to negligible level
  • Make diagnosis, prediction of response and its monitoring very precise
  • Make a step towards truly Personalized Medicine